Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17218400 | 1.00 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17219259 | 0.95 | MAOB (0.59) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17219256 | 0.95 | MAOB (0.59) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218438 | 0.93 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218441 | 0.93 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218188 | 0.92 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218190 | 0.92 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218724 | 0.87 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL17218720 | 0.87 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL4196342 | 0.86 | TSHR (0.44) | NPC1RAB9ASMN1; SMN2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940012-B1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9560850-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2940012-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | Sumitomo Chemical Company Limited (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | NPC1 4172/4885RAB9A 1095/4885SMN1; SMN2 4176/4885 |
| US-20150336908-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | RTN3, CYP51A1, TCOF1 | NPC1 1841/4885RAB9A 399/4885SMN1; SMN2 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.